JPMorgan Chase & Co. (JPM)
Verdict history · JPM
Every call Verdix has made on JPM.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call JPM yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NYSE · Financials · 2026-08-08 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
JPMorgan Chase's panel reveals a rare near-consensus: every archetype agrees it's a best-in-class bank with a fortress balance sheet, but five of six cautious voices object purely on price and timing at $357.52 — 15% above fair value, overbought on multiple timeframes, and met with $69M in insider selling. The debate isn't about quality; it's whether to pay up now or wait for the almost inevitable pullback toward $310–330 that would turn patience into profit.Level to watch
Key resistance 363+1.5% from 357.52
Next catalyst
Pullback to the accumulation zone: A decline to $310–330 would align the stock with Morningstar's $311 fair value and The Intrinsic-Value Modeler's $310–330 range, re-establishing the margin of safety that every cautious archetype requires before turning constructive.The panel's take
Verdict: WAIT · Conviction: MED · Last price: 357.52
This is a classic BUY vs WAIT split. Every cautious voice — The Moat Compounder, The Intrinsic-Value Modeler, The Forensic Skeptic, The Quality Rationalist, and The Margin-of-Safety Hunter — agrees JPM is a wonderful business; their objection is purely price/timing (overbought at all-time highs, 15% above Morningstar's $311 fair value, $69M insider selling, thin-volume breakout). No voice raises a genuine BUSINESS objection (thesis/moat/quality is intact). Per Step B: when all opposition is PRICE/TIMING — "great business, wrong price" — the synthesis is WAIT, not HOLD.
Key levels
Key levels · JPM
USD · as of 2026-08-08Analyst consensus target 357.52 USD · range 357.52–357.52
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran JPMorgan Chase & Co. past a panel of 7 legendary investors' frameworks.
The panel · 7 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: JPMorgan is a wonderful business with a wide moat built on low-cost deposits and deep switching costs, but at 15.3x trailing earnings and 15% above Morningstar's $311 fair value, the margin of safety isn't large enough to commit new capital. Conviction: Conviction is held back by one unresolved dependency: the thin-volume breakout above $341 needs a retest to confirm the new range, and without that confirmation, paying above intrinsic value lacks the required cushion.
The Margin-of-Safety HunterValue/Quantitative🔴 BearishHigh
Signal: The The Margin-of-Safety Hunter Number of approximately $264 stands far below the current price, and the product of P/E (15.34x) and P/B (2.69x) at 41.3x is nearly double the 22.5x maximum for defensive investors. Conviction: Conviction is reinforced by multiple independent, hard-to-dispute facts: the P/E and P/B each independently fail defensive criteria, and $69M in insider selling with zero buys confirms Mr. Market's enthusiasm is fully priced in.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: JPMorgan is the best-run bank in America with record revenue in every business line and a $484 billion net cash position that provides a half-trillion-dollar cushion — the balance sheet alone is worth half the market cap. Conviction: Conviction is pushed up by multiple reinforcing facts — record revenues across every segment, raised NII guidance to $96.5B, and 30% IB fee growth — though $69M in insider selling with zero insider buys is a yellow flag that keeps confidence from running hot.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: Using a justified P/B framework, the market is pricing in a perpetual ROE of roughly 19%, which exceeds even the current cyclical-peak 17.8% and is unsustainable without a permanent step-change in bank profitability. Conviction: Conviction is held back by one unresolved dependency: whether earnings can sustain above-trend growth for another 2–3 years or whether the credit cycle turns sooner than consensus expects, compressing multiples in the process.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The market has priced perfection with 89% bullish sentiment and a 0.55 put/call ratio, yet $69M in insider sales with zero purchases over 90 days is a loud warning that those closest to the business see limited further upside at current levels. Conviction: Low conviction reflects a contested assumption — that the earnings beat isn't already fully discounted — making the risk asymmetric to the downside regardless of JPM's quality.
The Disruptive-Innovation SeekerDisruptive Innovation⚫ Neutraln/a
Signal: JPMorgan is not creating disruption but is an incumbent adopting incremental innovations defensively, and the structural shift toward DeFi, digital wallets, and autonomous AI finance will erode its transaction fees and deposit base over a 5–7 year horizon. Conviction: Conviction is reinforced by the platform-level threat: when decentralized protocols operate at a marginal cost of zero, even the best-run legacy bank cannot compete on cost-to-income ratio over the long term.
The Quality RationalistMental Models/Quality⚫ NeutralMed
Signal: JPMorgan is unambiguously a wonderful business — wide moat, 17.8% ROE, disciplined capital allocation — but you're paying above intrinsic value for earnings running at a cyclical peak, and a three-year parabolic rally with thin volume at new highs is the kind of setup that historically produces a 15–20% mean reversion. Conviction: Conviction is held back by the unresolved dependency of whether the credit cycle turns before fundamentals catch up to the price, making patience the only rational choice at $357.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All seven archetypes agree JPMorgan is a high-quality, wide-moat business with best-in-class management under Jamie Dimon.
- Every cautious voice agrees the current price of $357.52 offers insufficient margin of safety relative to intrinsic value estimates clustered between $264 and $330.
- The $69M in insider selling with zero insider buying over 90 days is noted by nearly every archetype as a caution signal that the stock is at least fairly valued, if not rich.
- Both monthly and weekly RSI readings above 70 signal an overbought condition that warrants patience rather than chasing the breakout.
- No archetype raises a genuine business-quality objection — the moat, balance sheet, and execution are undisputed.
The real debate
- The GARP Operator sees record revenue in every business line and a $484B net cash position as justification for paying 15x earnings today, while the Margin-of-Safety Hunter sees the P/E × P/B product of 41.3x as nearly double the defensive maximum — these two frameworks cannot both be satisfied at the same price.
- The Moat Compounder and Quality Rationalist both view JPM as a wonderful business worth owning eventually, but only at a better price; the Disruptive-Innovation Seeker sees no price at which a legacy bank facing structural disruption from DeFi and autonomous finance is worth allocating capital — a genuine philosophical split on whether the business model itself has a long-term future.
- The Intrinsic-Value Modeler quantifies the core tension: the market is pricing in ~19% perpetual ROE that exceeds even today's cyclical-peak 17.8%, meaning the current price depends on a permanent step-change in bank profitability that history and mean-reversion suggest is unlikely.
The question it comes down to: Does JPMorgan's undeniable business quality and record-breaking execution justify paying a 15% premium above consensus intrinsic value at what multiple frameworks identify as a cyclical peak, or will the combination of overbought technicals, $69M in insider selling, and an eventual credit-cycle turn create a better opportunity to buy for long-term investors?
The bottom line
- Pullback to the accumulation zone: A decline to $310–330 would align the stock with Morningstar's $311 fair value and The Intrinsic-Value Modeler's $310–330 range, re-establishing the margin of safety that every cautious archetype requires before turning constructive.
- Breakout confirmation level: A weekly close above $363 on expanding volume would invalidate the thin-volume objection and confirm a new leg higher, flipping several neutral voices to bullish without waiting for a pullback.
- Key support to defend: A weekly close below $337.25 would mean former resistance failed to hold as support, confirming a false breakout and triggering the bearish case across the panel.
- Next catalyst: Q3 earnings in October will test whether 30% revenue growth and the raised $96.5B NII guidance are sustainable or whether the cyclical-peak narrative gains traction.
- Risk to monitor: Accelerating insider selling or a surprise rate cut that compresses net interest income would shift the balance further against the bulls, validating the Forensic Skeptic's asymmetric-risk thesis.
contact@verdixhq.com · Published 2026-08-08 · Prices as of 2026-08-08 · Time horizon: 3–12 months · No direct position held in JPM · JPM verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated